Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dusquetide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soligenix Launches Phase 2 Trial for SGX945 in Behçet's Disease
    Soligenix Launches Phase 2 Trial for SGX945 in Behçet's Disease

    14 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of-behcets-disease-302305230.html

    PR NEWSWIRE
    14 Nov 2024
    Share Share
    FDA Grants Soligenix
    FDA Grants Soligenix "Fast Track" Designation for Dusquetide

    08 Jan 2024

    // PRESS RELEASE

    https://ir.soligenix.com/2024-01-08-FDA-Grants-Soligenix-Fast-Track-Designation-for-Dusquetide-in-the-Treatment-of-Oral-Lesions-of-Behcets-Disease

    PRESS RELEASE
    08 Jan 2024
    Share Share
    Key Binding Characteristics of Dusquetide to Intracellular Protein Identified
    Key Binding Characteristics of Dusquetide to Intracellular Protein Identified

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-301558732.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    Dusquetide Shows +ve Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
    Dusquetide Shows +ve Anti-tumor Efficacy in Multiple Nonclinical Animal Studies

    04 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/dusquetide-demonstrates-positive-anti-tumor-efficacy-in-multiple-nonclinical-animal-studies-301452943.html

    PRNEWSWIRE
    04 Jan 2022
    Share Share
    Soligenix completes enrollment in phase 3 DOM-INNATE trial of SGX942
    Soligenix completes enrollment in phase 3 DOM-INNATE trial of SGX942

    26 Jun 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=129139&sid=2

    PHARMABIZ
    26 Jun 2020
    Share Share
    Soligenix Completes Enrollment in its Pivotal Ph 3 Trial of SGX942
    Soligenix Completes Enrollment in its Pivotal Ph 3 Trial of SGX942

    24 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-completes-enrollment-in-its-pivotal-phase-3-clinical-trial-of-sgx942-for-the-treatment-of-oral-mucositis-301082463.html

    PRNEWSWIRE
    24 Jun 2020
    Share Share